Old drug, new hope: thalidomide combo shows promise for kids with rare cancer
NCT ID NCT06470464
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed phase 2 trial tested a combination of thalidomide and three chemotherapy drugs (nab-paclitaxel, gemcitabine, epirubicin) in 20 children with relapsed or refractory yolk sac tumor, a rare germ cell cancer. The goal was to see if this new mix could shrink tumors or lower tumor markers. The study is the first to report this specific combination for children whose cancer returned after standard treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
thalidomide combined with nab-paclitaxel, gemcitabine, and epirubicin
What this could lead to
If it works, this could offer a new treatment option for children with yolk sac tumors that have not responded to standard chemotherapy.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to all patients. Thalidomide can cause side effects like nerve damage and blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shandong Cancer Hospital and Institute
Jinan, Shandong, 250117, China